New Neuroscience Center Launches Research into Alzheimer’s and Neural Circuitry

Per Yale School of Medicine's August 7 announcement, the Center for Translational Neuroscience of Alcohol has secured a five-year renewal from NIAAA. The 25-year-old center enters funding cycle six with a sharply defined target: the excitation-inhibition imbalance that sustains heavy drinking. It runs in parallel with UT Southwestern's newly operational North Texas Alzheimer's Disease Research Center, which Newswise covered August 6 alongside a five-year award expected to total $23 million.

The molecular lever

Two voltage-gated calcium channels anchor CTNA's working hypothesis. L-type VGCCs (CACNA1C) upregulate on cortical pyramidal neurons. R-type VGCCs (CACNA1E) downregulate on interneurons. Net circuit effect: cortical excitation rises while inhibitory drive weakens. The signature emerged from large-scale genetics work by Hang Zhou and Joel Gelernter, layered onto single-cell transcriptomics on post-mortem brain tissue led by Matthew Girgenti as a CTNA Pilot Project. CTNA frames the combined finding, for the first time, as a targetable neurobiological risk mechanism for heavy drinking — a direct translation of molecular neuroscience into clinical insight. John Krystal and Stephanie O'Malley direct the center; Kelly DeMartini coordinates administration.

Three coordinated projects

Project one (Girgenti): extend the single-cell transcriptomic analysis across an enlarged post-mortem cohort. Generate organoids from individuals with and without alcohol use disorder. Quantify how AUD risk genes reshape neuronal adaptation to alcohol exposure, then screen candidate anti-drinking compounds for repurposing potential.

Project two (Che, Taylor): isolate the microcircuit mechanisms through which genetic risk expresses itself as drinking behavior. Record brain activity while administering novel drugs designed to correct the circuit defect. Evaluate whether baseline E/I imbalance predicts anti-drinking effectiveness — a direct bridge from circuit readout to behavioral readout.

Project three: push the same compounds into clinical testing. Measure consumption reduction in heavy drinkers.

What to monitor

• Replication of CACNA1C upregulation and CACNA1E downregulation across independent post-mortem cohorts — single-cohort signatures do not generalize automatically.
• Organoid validation: whether AUD-risk-gene lines reproduce the predicted E/I shift under controlled alcohol exposure before any clinical inference is drawn.
• Microcircuit-to-behavior correlation: strength of the link between baseline excitation imbalance and drug-induced drinking reduction.
• NT-ADRC pipeline at UT Southwestern: ARGO-NULISA panel design, sample throughput, and biomarker targets beyond hypertension.